A Phase 3 interventional study of CSL312 in Hereditary Angioedema, sponsored by CSL Behring. Completed at 44 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-02.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Angioedemas, Hereditary by CSL Limited — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · CSL Limited.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 7th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 11 studies in Angioedemas, Hereditary by CSL Limited is open now, in 5 countries. Recruiting first, the newest first:
CSL Behring · Sites in United States, Austria, Canada and 2 more countries
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2021.
This study's enrollment of 171 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 61 across the 8 interventional studies, 259 across the 2 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Angioedemas, Hereditary by CSL Limited, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody administered subcutaneously
Biological: CSL312
Fully human immunoglobulin G subclass 4/lambda recombinant inhibitor monoclonal antibody
Also known as: Factor XIIa inhibitor monoclonal antibody, garadacimab
Number of Participants With Treatment-emergent Adverse Events (TEAE)
Time frame: Approximately up to 54 months
Percentage of Participants With TEAE
The percentage of participants was rounded to one place of decimal.
Time frame: Approximately up to 54 months
Number of TEAE
Time frame: Approximately up to 54 months
TEAE Rates Per Injection
The TEAE rate per injection was calculated as the number of TEAE/ total number of injections. The number of injections was defined as the total injections received by participants during the respective safety evaluation period.
Time frame: Approximately up to 54 months
TEAE Rates Per Participant Year
The TEAE rate per participant year was calculated as the total number of TEAE/ participant years. Participant years was defined as the sum of the time (in years) that participant were exposed to study treatment during the respective safety evaluation period.
Time frame: Approximately up to 54 months
The Time-normalized Number (Per Month) of Hereditary Angioedema (HAE) Attacks During the Run-in Period and Treatment Period
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*30.4375.
Time frame: Run-in Period: Up to Day 60 and Treatment Period: Approximately up to 52 months
The Time-normalized Number (Per Year) of HAE Attacks During Treatment Period
Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*365.25.
Time frame: Approximately up to 52 months
Percentage Reduction in the Attack Rate During the Treatment Period Compared to the Run-in Period
The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as: 100\*(1- time normalized number of HAE attacks per month during Treatment Period/time-normalized number of HAE attacks per month during Run-in Period).
Time frame: Run-in Period: Up to 60 days and Treatment Period: Approximately up to 52 months
Number of Participants With Percentage Reduction (of >=50%, >=70%, >=90%, and 100%) in HAE Attacks
The number of participants who achieved a percentage reduction in HAE attacks of \>=50% (also considered as responders), \>=70%, \>=90%, and 100% (attack free) during the Treatment Period compared with the Run-in Period. The percentage reduction in the time-normalized number of HAE attacks per month was calculated as 100\*\[1 - (time-normalized number of HAE attacks per month under CSL312 treatment / time-normalized number of HAE attacks per month during Run-in Period)\].
Time frame: Run-in Period: Up to Day 60 and Treatment Period: Approximately up to 52 months
The Time-normalized Number (Per Month) of HAE Attacks Requiring On-demand Treatment
Time-normalized number of HAE attacks per month requiring on demand treatment was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*30.4375.
Time frame: Approximately up to 52 months
The Time-normalized Number (Per Year) of HAE Attacks Requiring On-demand Treatment
Time-normalized number of HAE attacks requiring on demand treatment per year was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*365.25.
Time frame: Approximately up to 52 months
The Time-normalized Number (Per Month) of Moderate and/or Severe HAE Attacks
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\]\*30.4375.
Time frame: Approximately up to 52 months
The Time-normalized Number (Per Year) of Moderate and/or Severe HAE Attacks
Time-normalized number of moderate or severe HAE attacks per year during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks /length of participant treatment in days\]\*365.25.
Time frame: Approximately up to 52 months
Number of Participants Rating Their Response to Therapy as Good or Excellent
Number of participants rating their response to therapy as good or excellent was evaluated as per Subject's Global Assessment of Response to Therapy (SGART) questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure.
Time frame: At Months 12, 24, and 36
Percentage of Participants Rating Their Response to Therapy as Good or Excellent
Percentage of participants rating their response to therapy as good or excellent was evaluated as per SGART questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure. The percentage of participants was rounded to one place of decimal.
Time frame: At Months 12, 24, and 36
Number of Participants Experiencing Serious Adverse Events (SAE), Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
Time frame: Approximately up to 54 months
Percentage of Participants Experiencing SAE, Experiencing Death, Related TEAE, TEAE Leading to Study Discontinuation
The percentage of participants was rounded to one decimal place.
Time frame: Approximately up to 54 months
Number of Participants Experiencing TEAE by Severity
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
Time frame: Approximately up to 54 months
Percentage of Participants Experiencing TEAE by Severity
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one decimal place.
Time frame: Approximately up to 54 months
Number of Participants Experiencing Adverse Events of Special Interest (AESI)
The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.
Time frame: Approximately up to 54 months
Percentage of Participants Experiencing AESI
The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.
Time frame: Approximately up to 54 months
Number of Participants With Laboratory Findings Reported as TEAE
Time frame: Approximately up to 54 months
Percentage of Participants With Laboratory Findings Reported as TEAE
The percentage of participant was rounded to one place of decimal.
Time frame: Approximately up to 54 months
Number of Participants With Normal C1-esterase Inhibitor (nC1-INH) Experiencing TEAE
Time frame: Approximately up to 54 months
Percentage of Participants With nC1-INH Experiencing TEAE
Time frame: Approximately up to 54 months
Number of Participants With Anti-CSL312 Antibodies
Time frame: At Day 1, Months 6, 12, 36 and 43 (end of treatment [EOT])
Percentage of Participants With Anti-CSL312 Antibodies
The percentage of participants was rounded to one decimal place.
Time frame: At Day 1, Months 6, 12, 36 and 43 (EOT)
This study was conducted at 44 sites in 14 countries (Australia, Canada, Czechia, Germany, Hong Kong, Hungary, Israel, Japan, Netherlands, New Zealand, Russia, Spain, Taiwan, and United States of America).
| Milestone | CSL312 (Garadacimab) |
|---|---|
| Started | 161 |
| Completed | 146 |
| Not completed | 15 |
| Withdrew: Adverse event | 4 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Physician decision | 2 |
| Withdrew: Site terminated by sponsor due to war | 3 |
| Participants | Participants With c1-esterase Inhibitor (c1-INH) Hereditary Angioedema (HAE) |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAE) | 146 |
The percentage of participants was rounded to one place of decimal.
| Percentage of participants | Participants With c1-INH HAE |
|---|---|
| Percentage of Participants With TEAE | 91.8 |
| Events | Participants With c1-INH HAE |
|---|---|
| Number of TEAE | 1196 |
The TEAE rate per injection was calculated as the number of TEAE/ total number of injections. The number of injections was defined as the total injections received by participants during the respective safety evaluation period.
| Number of TEAE per injection | Participants With c1-INH HAE |
|---|---|
| TEAE Rates Per Injection | 0.20 |
The TEAE rate per participant year was calculated as the total number of TEAE/ participant years. Participant years was defined as the sum of the time (in years) that participant were exposed to study treatment during the respective safety evaluation period.
| Number of TEAE per participant year | Participants With c1-INH HAE |
|---|---|
| TEAE Rates Per Participant Year | 2.26 |
Time-normalized number of HAE attacks per month during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*30.4375.
| Number of HAE attacks per month | CSL312 (Garadacimab) |
|---|---|
| Per month (Run-in Period) | 2.85 (2.61 to 3.17) |
| Per month (Treatment Period) | 0.02 (0.00 to 0.02) |
Time-normalized number of HAE attacks per year during treatment was calculated per participant as: \[number of HAE attacks / length of participant treatment in days\]\*365.25.
| Number of HAE attacks per year | CSL312 (Garadacimab) |
|---|---|
| The Time-normalized Number (Per Year) of HAE Attacks During Treatment Period | 0.25 (0.00 to 0.28) |
The percentage reduction in the time-normalized number of HAE attacks was calculated within a participant as: 100\*(1- time normalized number of HAE attacks per month during Treatment Period/time-normalized number of HAE attacks per month during Run-in Period).
| Percentage reduction in HAE attacks | CSL312 (Garadacimab) |
|---|---|
| Percentage Reduction in the Attack Rate During the Treatment Period Compared to the Run-in Period | 95.41 ± 11.073 |
The number of participants who achieved a percentage reduction in HAE attacks of \>=50% (also considered as responders), \>=70%, \>=90%, and 100% (attack free) during the Treatment Period compared with the Run-in Period. The percentage reduction in the time-normalized number of HAE attacks per month was calculated as 100\*\[1 - (time-normalized number of HAE attacks per month under CSL312 treatment / time-normalized number of HAE attacks per month during Run-in Period)\].
| Participants | CSL312 (Garadacimab) |
|---|---|
| >= 50% | 158 |
| >= 70% | 155 |
| >= 90% | 139 |
| Attack free (Reduction of 100%) | 76 |
Time-normalized number of HAE attacks per month requiring on demand treatment was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*30.4375.
| Number of HAE attacks per month | CSL312 (Garadacimab) |
|---|---|
| The Time-normalized Number (Per Month) of HAE Attacks Requiring On-demand Treatment | 0.00 (0.00 to 0.02) |
Time-normalized number of HAE attacks requiring on demand treatment per year was calculated per participant as: \[number of HAE attacks requiring on demand treatment during treatment period / length of participant treatment in days\]\*365.25.
| Number of HAE attacks per year | CSL312 (Garadacimab) |
|---|---|
| The Time-normalized Number (Per Year) of HAE Attacks Requiring On-demand Treatment | 0.00 (0.00 to 0.25) |
Time-normalized number of moderate or severe HAE attacks per month during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks / length of participant treatment in days\]\*30.4375.
| Number of HAE attacks per month | CSL312 (Garadacimab) |
|---|---|
| The Time-normalized Number (Per Month) of Moderate and/or Severe HAE Attacks | 0.00 (0.00 to 0.02) |
Time-normalized number of moderate or severe HAE attacks per year during treatment period was calculated per participant as: \[number of moderate or severe HAE attacks /length of participant treatment in days\]\*365.25.
| Number of HAE attacks per year | CSL312 (Garadacimab) |
|---|---|
| The Time-normalized Number (Per Year) of Moderate and/or Severe HAE Attacks | 0.00 (0.00 to 0.23) |
Number of participants rating their response to therapy as good or excellent was evaluated as per Subject's Global Assessment of Response to Therapy (SGART) questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure.
| Participants | CSL312 (Garadacimab) |
|---|---|
| At Month 12 | 136 |
| At Month 24 | 130 |
| At Month 36 | 108 |
Percentage of participants rating their response to therapy as good or excellent was evaluated as per SGART questionnaire. SGART is a patient-reported outcome that represents the participant's overall response to treatment using the following ratings: (0) none: worse or no response at all, not acceptable, (1) poor: very little response, not acceptable, (2) fair: some response, acceptable but could be better, (3) good: good response, acceptable, and (4) excellent: excellent response, as good as can be imagined. Cumulative responses as "Good or Excellent" are reported for this outcome measure. The percentage of participants was rounded to one place of decimal.
| Percentage of Participants | CSL312 (Garadacimab) |
|---|---|
| At Month 12 | 93.8 |
| At Month 24 | 97.7 |
| At Month 36 | 94.7 |
| Participants | CSL312 (Garadacimab) |
|---|---|
| SAE | 14 |
| Experiencing Death | 0 |
| Related TEAE | 24 |
| TEAE leading to study discontinuation | 4 |
The percentage of participants was rounded to one decimal place.
| Percentage of participants | CSL312 (Garadacimab) |
|---|---|
| SAE | 8.7 |
| Experiencing Death | 0 |
| Related TEAE | 14.9 |
| TEAE leading to study discontinuation | 2.5 |
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.
| Participants | CSL312 (Garadacimab) |
|---|---|
| Mild | 121 |
| Moderate | 111 |
| Severe | 20 |
| Missing | 1 |
Severity of AE was assessed by the investigator and categorized as mild, moderate and severe. A mild AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. A moderate AE that is usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. A severe AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention. The percentage of participants was rounded to one decimal place.
| Percentage of participants | CSL312 (Garadacimab) |
|---|---|
| Mild | 75.2 |
| Moderate | 68.9 |
| Severe | 12.4 |
| Missing | 0.6 |
The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.
| Participants | CSL312 (Garadacimab) |
|---|---|
| Thromboembolic events (Investigator) | 0 |
| Abnormal bleeding events (Investigator) | 0 |
| Hypersensitivity including anaphylaxis (Investigator) | 0 |
The AESI defined for this study were thromboembolic events, abnormal bleeding events, and severe hypersensitivity including anaphylaxis. The AESI reported have been identified by investigators.
| Percenatge of participants | CSL312 (Garadacimab) |
|---|---|
| Thromboembolic events (Investigator) | 0 |
| Abnormal bleeding events (Investigator) | 0 |
| Hypersensitivity including anaphylaxis (Investigator) | 0 |
| Participants | CSL312 (Garadacimab) |
|---|---|
| Bacterial test positive | 6 |
| Urinary squamous epithelial cells increased | 4 |
| White blood cells urine positive | 2 |
| Crystal urine present | 2 |
| Red blood cells urine positive | 2 |
| White blood cell count increased | 2 |
| Neutrophil count increased | 1 |
| Bilirubin conjugated increased | 1 |
| Blood bilirubin increased | 1 |
| Blood calcium decreased | 1 |
| Blood creatinine increased | 1 |
| Crystalluria | 1 |
| Cystitis | 1 |
| Fibrin D dimer increased | 1 |
| Gastroenteritis | 1 |
| Hyperbilirubinaemia | 1 |
| Lymphocyte count decreased | 1 |
| Neutrophil count decreased | 1 |
| Nitrite urine present | 1 |
| Platelet count increased | 1 |
| Protein urine present | 1 |
| Specific gravity urine increased | 1 |
| Thrombocytopenia | 1 |
| Urinary occult blood positive | 1 |
| Urinary sediment present | 1 |
| Urinary tract infection | 1 |
| Urine analysis abnormal | 1 |
| Urine ketone body present | 1 |
The percentage of participant was rounded to one place of decimal.
| Percentage of Participants | CSL312 (Garadacimab) |
|---|---|
| Bacterial test positive | 3.7 |
| Urinary squamous epithelial cells increased | 2.5 |
| White blood cells urine positive | 1.2 |
| Crystal urine present | 1.2 |
| Red blood cells urine positive | 1.2 |
| White blood cell count increased | 1.2 |
| Neutrophil count increased | 0.6 |
| Bilirubin conjugated increased | 0.6 |
| Blood bilirubin increased | 0.6 |
| Blood calcium decreased | 0.6 |
| Blood creatinine increased | 0.6 |
| Crystalluria | 0.6 |
| Cystitis | 0.6 |
| Fibrin D dimer increased | 0.6 |
| Gastroenteritis | 0.6 |
| Hyperbilirubinaemia | 0.6 |
| Lymphocyte count decreased | 0.6 |
| Neutrophil count decreased | 0.6 |
| Nitrite urine present | 0.6 |
| Platelet count increased | 0.6 |
| Protein urine present | 0.6 |
| Specific gravity urine increased | 0.6 |
| Thrombocytopenia | 0.6 |
| Urinary occult blood positive | 0.6 |
| Urinary sediment present | 0.6 |
| Urinary tract infection | 0.6 |
| Urine analysis abnormal | 0.6 |
| Urine ketone body present | 0.6 |
| Participants | Participants With nC1-INH HAE |
|---|---|
| Number of Participants With Normal C1-esterase Inhibitor (nC1-INH) Experiencing TEAE | 2 |
| Percenatge of participants | Participants With nC1-INH HAE |
|---|---|
| Percentage of Participants With nC1-INH Experiencing TEAE | 100 |
| Participants | CSL312 (Garadacimab) |
|---|---|
| Day 1: Positive | 1 |
| Month 6: Positive | 1 |
| Month 12: Positive | 4 |
| Month 24: Positive | 0 |
| Month 36: Positive | 0 |
| EOT: Positive | 2 |
The percentage of participants was rounded to one decimal place.
| Percentage of participants | CSL312 (Garadacimab) |
|---|---|
| Day 1: Positive | 0.6 |
| Month 6: Positive | 0.6 |
| Month 12: Positive | 2.5 |
| Month 24: Positive | 0 |
| Month 36: Positive | 0 |
| EOT: Positive | 1.2 |
Collected over Approximately up to 54 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CSL312 (Garadacimab) | 0/161 (0%) | 14/161 (8.7%) | 147/161 (91.3%) |
| Event | CSL312 (Garadacimab) |
|---|---|
| COVID-19Infections and infestations | 2/161 |
| Appendicitis perforatedInfections and infestations | 1/161 |
| GastroenteritisInfections and infestations | 1/161 |
| Gastroenteritis viralInfections and infestations | 1/161 |
| SinusitisInfections and infestations | 1/161 |
| Craniofacial injuryInjury, poisoning and procedural complications | 1/161 |
| Hand fractureInjury, poisoning and procedural complications | 1/161 |
| Hereditary angioedemaCongenital, familial and genetic disorders | 1/161 |
| Abdominal incarcerated herniaGastrointestinal disorders | 1/161 |
| Food allergyImmune system disorders | 1/161 |
| Event | CSL312 (Garadacimab) |
|---|---|
| COVID-19Infections and infestations | 67/161 |
| NasopharyngitisInfections and infestations | 45/161 |
| InfluenzaInfections and infestations | 17/161 |
| HeadacheNervous system disorders | 15/161 |
| Upper respiratory tract infectionInfections and infestations | 14/161 |
| Injection site erythemaGeneral disorders | 13/161 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/161 |
| Abdominal painGastrointestinal disorders | 11/161 |
| ToothacheGastrointestinal disorders | 11/161 |
| SinusitisInfections and infestations | 10/161 |
All Treated Participants (ATP) analysis set consisted of all participants in the Screened analysis set who were assigned to treatment.
| Age, Continuous(Years) | CSL312 (Garadacimab) |
|---|---|
| Mean | 42.3 ± 15.31 |
| Age, Customized(Participants) | CSL312 (Garadacimab) |
|---|---|
| <=18 years | 12 |
| Between 18 and 64 years | 134 |
| >=65 years | 15 |
| Sex: Female, Male(Participants) | CSL312 (Garadacimab) |
|---|---|
| Female | 101 |
| Male | 60 |
| Ethnicity (NIH/OMB)(Participants) | CSL312 (Garadacimab) |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 150 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | CSL312 (Garadacimab) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 22 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 135 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Ran from Mar 2021 to primary completion in Nov 2025, 55 months.
Results were first posted in Jun 2026, 6 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 55 months is above that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garadacimab